A Rare Case Report of Multifocal Para-aortic and Para-vesical Paragangliomas

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Aug 25

PMID 36004346

Authors

San-Chao Xiong

Xing-Peng Di

Meng-Ni Zhang

Kan Wu

Xiang Li

Affiliations

Soon will be listed here.

Abstract

Background: Paragangliomas (PGLs) are uncommon tumors of uncertain malignant potential. Multifocal paragangliomas are scarcely reported in the literature.

Case Summary: A 25-year-old male patient was reported for the first time with multifocal para-aortic and para-vesical PGLs. The diagnosis was identified by blood catecholamine tests and enhanced CT scan and MIBG scintigraphy. A resection surgery was performed for treatment and the immunochemistry test of the tumors presented the features of PGL.

Conclusion: A case of multifocal para-aortic and para-vesical PGLs confirmed by the catecholamine test, enhanced CT, and MIBG scintigraphy is presented. The cooperation of experienced surgeons, anesthesiologists, and endocrinologists was critical in treatment.

References

Andersen K, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, Christensen N . Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Cancer Treat Rev. 2010; 37(2):111-9. DOI: 10.1016/j.ctrv.2010.07.002. View

Kong J, Zheng J, Wu J, Wu S, Cai J, Diao X . Development of a radiomics model to diagnose pheochromocytoma preoperatively: a multicenter study with prospective validation. J Transl Med. 2022; 20(1):31. PMC: 8760711. DOI: 10.1186/s12967-022-03233-w. View

Inaki A, Shiga T, Tsushima Y, Jinguji M, Wakabayashi H, Kayano D . An open-label, single-arm, multi-center, phase II clinical trial of single-dose [I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma. Ann Nucl Med. 2021; 36(3):267-278. PMC: 8897386. DOI: 10.1007/s12149-021-01699-0. View

Tanabe A, Naruse M . Recent advances in the management of pheochromocytoma and paraganglioma. Hypertens Res. 2020; 43(11):1141-1151. DOI: 10.1038/s41440-020-0531-0. View

Tzikos G, Menni A, Cheva A, Pliakos I, Tsakona A, Apostolidis S . Composite Paraganglioma of the Celiac Trunk: A Case Report and a Comprehensive Review of the Literature. Front Surg. 2022; 9:824076. PMC: 8901723. DOI: 10.3389/fsurg.2022.824076. View

Whalen R, Althausen A, Daniels G . Extra-adrenal pheochromocytoma. J Urol. 1992; 147(1):1-10. DOI: 10.1016/s0022-5347(17)37119-7. View

Stolk R, Bakx C, Mulder J, Timmers H, Lenders J . Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?. J Clin Endocrinol Metab. 2013; 98(3):1100-6. DOI: 10.1210/jc.2012-3669. View

Papavramidis T, Michalopoulos N, Georgia K, Kesisoglou I, Valentini T, Georgia R . Retroperitoneal ganglioneuroma in an adult patient: a case report and literature review of the last decade. South Med J. 2009; 102(10):1065-7. DOI: 10.1097/SMJ.0b013e3181b2fd37. View

Hadrava Vanova K, Pang Y, Krobova L, Kraus M, Nahacka Z, Boukalova S . Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma. J Natl Cancer Inst. 2021; 114(1):130-138. PMC: 8755484. DOI: 10.1093/jnci/djab158. View

10.

Baguet J, Hammer L, Mazzuco T, Chabre O, Mallion J, Sturm N . Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004; 150(5):681-6. DOI: 10.1530/eje.0.1500681. View

11.

Kavinga Gunawardane P, Grossman A . Phaeochromocytoma and Paraganglioma. Adv Exp Med Biol. 2016; 956:239-259. DOI: 10.1007/5584_2016_76. View

12.

Prejbisz A, Lenders J, Eisenhofer G, Januszewicz A . Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011; 29(11):2049-60. DOI: 10.1097/HJH.0b013e32834a4ce9. View

13.

Guerrero M, Schreinemakers J, Vriens M, Suh I, Hwang J, Shen W . Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009; 209(6):727-32. DOI: 10.1016/j.jamcollsurg.2009.09.022. View

14.

Usuda H, Emura I . Composite paraganglioma-ganglioneuroma of the urinary bladder. Pathol Int. 2005; 55(9):596-601. DOI: 10.1111/j.1440-1827.2005.01875.x. View

15.

Mete O, Asa S, Gill A, Kimura N, de Krijger R, Tischler A . Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022; 33(1):90-114. DOI: 10.1007/s12022-022-09704-6. View

16.

Ariton M, Juan C, AvRuskin T . Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract. 2001; 6(3):249-52. DOI: 10.4158/EP.6.3.249. View

17.

Plouin P, Amar L, Dekkers O, Fassnacht M, Gimenez-Roqueplo A, Lenders J . European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016; 174(5):G1-G10. DOI: 10.1530/EJE-16-0033. View

18.

Jacobson A, Deng H, Lombard J, Lessig H, Black R . 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010; 95(6):2596-606. DOI: 10.1210/jc.2009-2604. View

19.

Lenders J, Duh Q, Eisenhofer G, Gimenez-Roqueplo A, Grebe S, Murad M . Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(6):1915-42. DOI: 10.1210/jc.2014-1498. View

20.

Kamai T, Murakami S, Arai K, Nishihara D, Uematsu T, Ishida K . Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation. BMC Cancer. 2022; 22(1):289. PMC: 8931959. DOI: 10.1186/s12885-022-09415-5. View